SELLAS Life Sciences Group, Inc. Profile Avatar - Palmy Investing

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunot…

Biotechnology
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

SELLAS Life Sciences Group, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of SLS's Analysis
CIK: 1390478 CUSIP: 81642T209 ISIN: US81642T2096 LEI: - UEI: -
Secondary Listings
SLS has no secondary listings inside our databases.